Discontinue Aspirin and Continue Enoxaparin Alone
For a patient with atrial fibrillation on therapeutic enoxaparin, aspirin should be discontinued immediately. Combining aspirin with anticoagulation provides no additional stroke protection but significantly increases bleeding risk, particularly intracranial hemorrhage 1.
Rationale for Stopping Aspirin
The evidence is clear that combining antiplatelet agents with anticoagulation in AF patients does not reduce stroke risk but substantially increases major bleeding 1. The 2006 ACC/AHA/ESC guidelines explicitly state that "combinations of oral anticoagulants plus antiplatelet agents have not generally shown reduced risks of hemorrhage or augmented efficacy over adjusted-dose anticoagulation alone" and that "combining aspirin with an oral anticoagulant at higher intensities may accentuate intracranial hemorrhage, particularly in elderly AF patients" 1.
Recent research confirms this: a 2026 study demonstrated that adding low-dose aspirin to anticoagulation in AF patients without atherosclerotic disease significantly increased major bleeding (5.74 vs 1.37 per 100 patient-years) without reducing ischemic events 2.
Managing Anticoagulation with Enoxaparin
Therapeutic enoxaparin is an acceptable bridge or temporary anticoagulation strategy for AF, though it should be transitioned to oral anticoagulation when feasible 1, 3:
- Low-molecular-weight heparins have pharmacological advantages over unfractionated heparin, including longer half-life and more predictable bioavailability 1
- Enoxaparin use in AF is based on extrapolation from venous thromboembolism data and observational studies 1
- Therapeutic dosing is appropriate for patients at moderate-to-high stroke risk (CHADS₂ score ≥1) 4
Transition Strategy
Plan to transition from enoxaparin to oral anticoagulation (warfarin INR 2.0-3.0 or a DOAC) for long-term management 5, 6:
- For patients with CHADS₂ score ≥2 (high risk): oral anticoagulation is strongly recommended 5
- For patients with CHADS₂ score of 1 (intermediate risk): oral anticoagulation is recommended over aspirin 5
- DOACs (particularly dabigatran 150 mg twice daily) are suggested over warfarin when available 5
Special Considerations
Monitor anti-factor Xa levels only in specific high-risk situations 7:
- Extremes of body weight (very low or obese patients)
- Renal insufficiency
- Pregnancy
- Otherwise, routine monitoring is not necessary
When Aspirin Might Be Reconsidered
Aspirin should only be added back if the patient develops:
- Acute coronary syndrome: Use aspirin temporarily (≤1 week) with clopidogrel plus anticoagulation, then stop aspirin and continue clopidogrel with anticoagulation for up to 12 months 8, 9
- Recent PCI with stenting: Similar approach with early aspirin cessation 8, 9
For stable coronary artery disease, anticoagulation alone provides adequate protection against both cerebral and myocardial ischemic events 1.
Common Pitfalls to Avoid
- Do not continue aspirin "just in case" - this is the most common error and significantly increases bleeding risk without benefit
- Do not use reduced-dose enoxaparin for stroke prevention unless the patient has low thromboembolic risk or renal impairment 4
- Do not delay transition to oral anticoagulation - enoxaparin is intended as bridging therapy, not long-term management for AF